PT-141 (Bremelanotide) for Female Desire: The Only FDA-Approved Peptide for HSDD

The Only FDA-Approved Peptide for Female Desire

There aren't many molecules you can point to and say, 'this is FDA-approved specifically for female sexual desire.' Flibanserin (Addyi) is one. Bremelanotide — research name PT-141, brand name Vyleesi — is the other. Between the two, PT-141 is the one that works as a peptide, on-demand, through a specific brain pathway rather than by adjusting daily neurotransmitter balance.

The FDA approved bremelanotide in June 2019 for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.^[1] That's a specific and meaningful approval: the target population is women without a identifiable medical, psychiatric, or relationship cause for their low desire — in other words, women whose desire has dropped without a reason the existing medical toolkit can easily address.

This article walks through what PT-141 actually is, how it works, what the research shows, how it fits into broader women's sexual health protocols, and what a patient should understand before considering it.

What PT-141 Is, Chemically

PT-141 is a short peptide — seven amino acids — engineered from a longer naturally-occurring peptide called alpha-melanocyte-stimulating hormone (α-MSH). It was originally studied in the 1990s under the name PT-141 as a derivative of Melanotan II, a peptide developed to induce skin tanning by activating melanocortin receptors.^[1]

During the tanning research, investigators noticed an unexpected side effect: male subjects reported spontaneous erections and increased sexual desire. That observation pulled the molecule into a different research track — not as a tanning agent, but as a sexual health compound. Palatin Technologies acquired development rights and pursued FDA approval through multiple clinical trial phases over roughly fifteen years, initially for male erectile dysfunction, then for female HSDD where the Phase 3 results were stronger.

The mechanism is through melanocortin receptors — specifically MC3R and MC4R, which are expressed in the hypothalamus and other central nervous system areas that regulate sexual behavior. This is a different mechanism from the PDE5 inhibitors used in male ED (Viagra, Cialis), which work peripherally on blood flow. PT-141 works centrally — it triggers the brain's desire pathway directly.

What the Trial Data Actually Shows

The pivotal Phase 3 data for Vyleesi came from two randomized controlled trials (RECONNECT-1 and RECONNECT-2) that together enrolled about 1,200 premenopausal women with diagnosed HSDD.^[1] The primary outcomes were change in desire score (measured on a validated scale called the Female Sexual Function Index, Desire Domain) and change in sexual distress (measured on the Female Sexual Distress Scale).

On both measures, bremelanotide produced statistically significant improvements versus placebo — but the effect sizes were modest, not dramatic. In RECONNECT-1, about 25% of bremelanotide patients met a predefined responder threshold for improved desire, versus 17% on placebo. Similar numbers emerged in RECONNECT-2. The typical pattern is: a meaningful fraction of treated women experience a real effect, a smaller fraction experience a strong effect, and a substantial fraction see no change beyond placebo.

Real-world patient satisfaction in the years since approval has been higher than the trial effect sizes would suggest — which is a pattern seen with several on-demand sexual health medications, where trial designs don't fully capture the experience of motivated users. It's also worth acknowledging that patient satisfaction data from real-world use is subject to self-selection — women who don't find it useful stop taking it and don't generate continuing data.

The honest read: PT-141 works for a meaningful minority of women with HSDD. It is not a universal solution, and it's not a dramatic change for most users. For the subset who do respond well, the effect is real and the on-demand format is unusually convenient compared to daily options.

How It's Dosed and Administered

The FDA-approved branded product (Vyleesi) comes as a subcutaneous autoinjector at a fixed dose (1.75 mg per dose). It's self-administered, typically injected into the thigh or abdomen 45 minutes before anticipated sexual activity. The effect has been characterized as lasting several hours, with the FDA label limiting use to no more than once in a 24-hour period and no more than eight doses per month.

Compounded preparations — from 503A compounding pharmacies — offer alternative routes: sublingual troche (dissolved under the tongue) or intranasal spray. These are off-label from a formulation standpoint (the FDA only approved the autoinjector) but are used in clinical practice because some patients prefer them to the subcutaneous route. Your prescriber determines which formulation is appropriate based on your preference and clinical situation.

Dosing is on-demand, not daily. That's a meaningful feature for this category of intervention — you're not building up a daily medication with steady-state pharmacology, you're taking it when you want the effect. The cost structure, safety profile, and decision-making all reflect that.

Side Effects and Contraindications

The most common side effect is transient mild nausea, which occurs in a meaningful fraction of users and is typically most pronounced on the first few doses. It usually diminishes with repeated use. Other common but transient effects include flushing, injection-site reactions, and headache.

A subset of users experience a transient rise in blood pressure in the hours after dosing. In most patients, this is mild and self-limiting. In patients with baseline cardiovascular risk, it's more than a nuisance — it's a real contraindication that requires screening. The FDA label specifies that Vyleesi is contraindicated in patients with uncontrolled hypertension or significant cardiovascular disease. Any legitimate prescriber will screen for these conditions with baseline vitals and health history review before starting.

A rarer side effect worth knowing about: focal hyperpigmentation. Because PT-141 activates melanocortin receptors involved in skin pigmentation (remember, the molecule was originally developed as a tanning agent), a small percentage of users develop darker patches of skin — usually on the face, gums, or breasts — with repeated dosing. It's typically reversible on discontinuation. It's more common in patients with darker baseline skin tone.

Pregnancy and breastfeeding are also contraindications for PT-141; the safety data for those populations is insufficient.

Where PT-141 Fits in Women's Sexual Health Protocols

PT-141 is a legitimate single-molecule option for desire, and some women do well on it alone. The reality for most women, though, is that female sexual response has multiple independent components — central desire (brain), emotional bonding and context (relationship and arousal chemistry), and local physical response (blood flow and tissue). PT-141 targets only the first of these.

That's why many clinical providers who prescribe PT-141 pair it with other components — oxytocin for the bonding and emotional context dimension, and a topical compounded arousal cream for the local physical response. Each addresses something the others don't.

On-demand doesn't necessarily mean one-dimensional, but PT-141 alone is a single lever. For women where desire is the dominant issue and the emotional / physical pieces are intact, PT-141 alone may work well. For women where multiple dimensions are struggling — desire, emotional connection, and physical response all diminished — a multi-component protocol tends to produce better results than any single intervention.

For broader framing of this approach, see our overview of the Women's Sexual Health Stack, which discusses how PT-141, oxytocin, and arousal cream each address a different piece of the response system.

Legitimately Accessing PT-141

PT-141 requires a prescription from a licensed physician. The prescriber confirms the patient is in the target population (premenopausal HSDD for the on-label indication, or documented off-label medical necessity), reviews cardiovascular history and medications, and writes a prescription that can be filled either as the branded Vyleesi autoinjector or as a compounded preparation through a 503A pharmacy.

What to look for in a legitimate prescriber:

- Baseline cardiovascular screening. Blood pressure measurement, cardiac history review. Uncontrolled hypertension is a real exclusion. A prescriber who skips this is a red flag. - Individual dose adjustment. Some women do better at the lower end of the dose range, others need more (via compounded formulations). Dose titration is part of good care. - Full medical history, not a checkbox intake. Mental health history, relationship context, current medications — all relevant for whether PT-141 is appropriate. - Follow-up structure. 4-8 week check-in to assess response and adjust dose or approach if results are limited. - Compliance with the FDA indication or documented off-label rationale. Off-label prescribing is legal and common, but a legitimate prescriber documents the rationale rather than prescribing reflexively.

What to avoid: any prescriber who won't do cardiovascular screening, any platform promising dramatic or universal results, any protocol that skips the clinical review in favor of automated approval. Female sexual health is a category where marketing aggression runs ahead of clinical rigor, and PT-141 specifically has a real side-effect profile that demands proper screening. Quality prescribers are worth finding.

For Pepvio's current pricing on the full Women’s Sexual Health Stack (which includes PT-141 as one of three components), see the protocol page.